Hiwa K. Saeed Email & Phone Number

Leeds, England, United Kingdom

As an Application Scientist, I facilitate the seamless integration of advanced scientific knowledge into the pharmaceutical industry. By utilising sophisticated in silico tools, I ensure the safety, effectiveness, and regulatory compliance of pharmaceutical products. Bridging the gap between science and industrial applications, with a focus on evaluating mutagenic impurities in Active Pharmaceutical Ingredients (APIs). Providing comprehensive training and support services to users of In Silico tools. Created plans and communicated deadlines to complete projects on time.

Sheffield, England, United Kingdom

As a Postdoctoral Researcher, I led the development of novel antimicrobial agents, using advanced techniques to evaluate their effectiveness against various bacteria, intending to advance infection control in healthcare. Led research on the development of novel antimicrobial materials. Assessed their efficacy against various bacteria using electron microscopy.

New York, United States

Contributed to the development of antibody-drug conjugates (ADCs) with gold linkers, advancing targeted cancer therapies for better patient outcomes. Managed the development of antibody-drug conjugates (ADCs) project, and advanced targeted cancer therapies for improved patient outcomes. Designed and synthesised ADCs with gold(I) compounds and a maleimide linker for easy conjugation to monoclonal antibodies. Executed advanced biophysical and molecular imaging techniques to analyse their interactions with antibodies, demonstrating proficiency in molecular imaging methods.

Hilo, Hawaii, United States

Developed hydrogen ion pairs from various biguanides and their evaluation and development into nanoparticles. These versatile nanoparticles showed potential for diverse medical applications, from diabetes and anti-fungal treatments to cancer and cardiovascular therapy, contributing to innovative healthcare solutions. Evaluated physicochemical properties of developed formulations. Innovated ionic liquids of various biguanides and Benzimidazoles, their evaluation and development into nanoparticles for various applications like anti-diabetic, anti-fungal, anti-cancer and cardiovascular. Established novel strategies for HIV prevention and development and evaluation of thermosensitive.  Advanced and validated analytical methodologies to support various drug analyses such as HPLC, MS, IR, and NMR.

Cardiff, Wales, United Kingdom

Focused on designing organic DNA binders for Lateral Flow Assays, improving diagnostic accuracy and efficiency.  Synthesised and developed methods for crafting optoelectronically active nucleic acid binders, with a focus on naphthalimide derivatives, resulting in enhanced accuracy and efficiency in Lateral Flow Assays. Implemented biophysical studies to investigate their properties for innovative detection assays, ultimately contributing to advancements in diagnostic technologies.

Sheffield, England, United Kingdom

Developed luminescent metal complexes designed to specifically target biomolecules and cellular structures. These compounds were engineered to function as structural probes for advanced microscopy techniques and also served as potential therapeutic leads. Synthesised and characterised anticancer ruthenium metal complexes using a range of analytical and biophysical techniques. Employed these complexes as versatile biological probes for detailed studies. Conducted research aimed at uncovering new insights into therapeutic applications. Investigated the interactions between these complexes and biological molecules.